PD-1PD-L1抑制剂在肿瘤免疫治疗中的研究进展-中国肿瘤临床.PDF

1178 中国肿瘤临床2015年第42卷第24期 ChinJClinOncol2015.Vol.42.No.24 综 述 · · PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展* 叶因涛 王晨 孙蓓 摘要 肿瘤免疫治疗是目前肿瘤领域的研究热点，是一种疗效显著的肿瘤治疗模式。程序性死亡受体PD-1（programmed celldeath-1）是一种重要的免疫抑制分子，主要在激活的T细胞和B细胞中表达。肿瘤细胞中高表达PD-1的配体PD-L1，导致肿 瘤微环境中PD-1通路持续激活。PD-1/PD-L1抑制剂可以阻断PD-1与PD-L1的结合，阻断负向调控信号，使T细胞恢复活性， 从而增强免疫应答。近期研究发现PD-1和PD-L1的抑制剂在多种肿瘤类型中疗效显著。本文对PD-1/PD-L1抑制剂的现况及 其对不同肿瘤类型临床疗效的研究进展进行综述。 关键词 免疫治疗 抗肿瘤 PD-1抑制剂 PD-L1抑制剂 doi:10.3969/j.issn.1000-8179.2015.24.803 Research progress on PD- 1/PD- L1 inhibitors in tumor immuno- therapy Yintao YE, Chen WANG, Bei SUN Correspondence to: Pei SUN; E-mail: sunpei003@ Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China This work was supported by the Tianjin Municipal Health and Family Planning Commission Project of Chinese and Western Medi- cine Research (No. 2015066) and the Young Scientist Funds of Tianjin Medical University (No. 2014KYQ06) Abstract Tumor immunotherapy is highlighted in tumor studies and has a remarkable curative effect on tumors. Programmed cell death- 1 (PD- 1), which is mainly expressed in activated T and B cells, is an important immune inhibitory molecule. Its ligand PD- L 1 could be highly expressed in cancer cells, and the PD- 1 pathway shows sustained activation in a tumor micro-environment. PD- 1/ PD-L 1 inhibitors can block the combination of PD- 1 and PD-L1, inhibit negative to regulatory signals, and restore the activity of T cells, thereby enhancing immune response. Recent studies showed that PD- 1 and PD-L1 inhibitors have been effective in many tumor types. This review summarizes PD- 1/PD-L 1 inhibitors and their clinical effects on different tumor types. Keywords: immunotherapy, a